Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting Long-Term Global Outcome after Traumatic Brain Injury: Development of a Practical Prognostic Tool Using the Traumatic Brain Injury Model Systems National Database.
Walker WC, Stromberg KA, Marwitz JH, Sima AP, Agyemang AA, Graham KM, Harrison-Felix C, Hoffman JM, Brown AW, Kreutzer JS, Merchant R. Walker WC, et al. Among authors: stromberg ka. J Neurotrauma. 2018 Jul 15;35(14):1587-1595. doi: 10.1089/neu.2017.5359. Epub 2018 May 16. J Neurotrauma. 2018. PMID: 29566600 Free PMC article.
Response to Foks et al. (doi: 10.1089/neu.2018.5979): Why Our Long-Term Functional Prognosis Tools are a Valuable Contribution to the Traumatic Brain Injury Outcome Literature.
Walker WC, Sima AP, Hoffman JM, Harrison-Felix C, Agyemang AA, Stromberg KA, Marwitz JH, Brown AW, Graham KM, Merchant R, Kreutzer JS. Walker WC, et al. Among authors: stromberg ka. J Neurotrauma. 2019 Apr 15;36(8):1384-1385. doi: 10.1089/neu.2018.6069. Epub 2018 Dec 4. J Neurotrauma. 2019. PMID: 30375265 Free PMC article. No abstract available.
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
P van Valenberg FJ, van der Heijden AG, Cutie CJ, Bhanvadia S, Keegan KA, Hampras S, Sweiti H, Maffeo JC, Jin S, Chau A, Reynolds DL, Iarossi C, Kelley A, Li X, Stromberg KA, Michiel Sedelaar JP, Steenbruggen JJO, Somford DM, Alfred Witjes J. P van Valenberg FJ, et al. Among authors: stromberg ka. Eur Urol Open Sci. 2024 Feb 16;62:8-15. doi: 10.1016/j.euros.2024.01.013. eCollection 2024 Apr. Eur Urol Open Sci. 2024. PMID: 38585206 Free PMC article.
Reply by Authors.
Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, Guerrero-Ramos F, Scarpato KR, Hafron JM, Messing EM, Cutie CJ, Maffeo JC, Raybold B, Chau A, Stromberg KA, Keegan KA. Tyson MD, et al. Among authors: stromberg ka. J Urol. 2023 May;209(5):900. doi: 10.1097/JU.0000000000003195.02. Epub 2023 Apr 7. J Urol. 2023. PMID: 37026638 No abstract available.
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, Guerrero-Ramos F, Scarpato KR, Hafron JM, Messing EM, Cutie CJ, Maffeo JC, Raybold B, Chau A, Stromberg KA, Keegan KA. Tyson MD, et al. Among authors: stromberg ka. J Urol. 2023 May;209(5):890-900. doi: 10.1097/JU.0000000000003195. Epub 2023 Apr 7. J Urol. 2023. PMID: 37026631 Clinical Trial.
16 results